Company intelligence / Profile preview
Iksuda Therapeutics
Newcastle upon Tyne or London*, United Kingdomiksuda.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Iksuda’s clinical-stage ADC pipeline includes multiple programs targeting both hematologic malignancies and solid tumors. Lead assets such as the anti-CD19 ADC (“IKS03”) and HER2-targeting ADC (“IKS014”) have entered Phase I clinical trials. The company emphasizes tumor-selective activation of novel prodrug payloads to improve therapeutic index. Early results validate their approach for improved safety/efficacy profiles compared to traditional ADC designs.[1][5][6]
Pipeline breadth:
At least four named clinical/preclinical programs plus an expanding early-stage portfolio.[5]- Therapeutic areas
- Oncology
- Modalities
- Antibody-drug conjugates (ADCs)Protein alkylating payloads (ProAlk)DNA alkylating payloads[1][6]
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
Request access →03
Partnerships
LegoChem Biosciences / LigaChem BioSciences – licensing of ConjuAll platform, anti-CD19 & HER2-directed assets, major equity investment ($25M in March 2025)[7][5].Research collaborations with leading academic institutions for binder discovery/enhancement.[4]
Beyond the preview
Go deeper on Iksuda Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Iksuda Therapeutics.